Semaglutide Drug Safety Signals: Global Pharmacovigilance Analysis
Descriptive analysis from VigiAccess global pharmacovigilance database characterizes drug-related problems associated with semaglutide across international reporting systems.
Quick Facts
What This Study Found
Descriptive analysis from VigiAccess global pharmacovigilance database characterizes drug-related problems associated with semaglutide across international reporting systems.
Key Numbers
Six GLP-1 drugs analyzed: exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide from the WHO VigiAccess database.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Descriptive analysis from VigiAccess global pharmacovigilance database characterizes drug-related pr
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.
- Published In:
- Current drug safety (2025)
- Authors:
- Amirthalingam, Palanisamy(3)
- Database ID:
- RPEP-09929
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Descriptive analysis from VigiAccess global pharmacovigilance database characterizes drug-related problems associated with semaglutide across international reporting systems.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09929APA
Amirthalingam, Palanisamy. (2025). A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.. Current drug safety. https://doi.org/10.2174/0115748863367086250420011411
MLA
Amirthalingam, Palanisamy. "A Descriptive Analysis from VigiAccess on Drug-related Problems Associated with the Glucagon-like Peptide-1 Receptor Agonists.." Current drug safety, 2025. https://doi.org/10.2174/0115748863367086250420011411
RethinkPeptides
RethinkPeptides Research Database. "A Descriptive Analysis from VigiAccess on Drug-related Probl..." RPEP-09929. Retrieved from https://rethinkpeptides.com/research/amirthalingam-2025-a-descriptive-analysis-from
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.